Press release from Marketwire
StrixNB(TM) Significantly Reduces Bad Breath in Dogs
Thursday, April 04, 2013
StrixNB(TM) Significantly Reduces Bad Breath in Dogs08:00 EDT Thursday, April 04, 2013
WINNIPEG, MANITOBA--(Marketwired - April 4, 2013) - Kane Biotech Inc. (TSX VENTURE:KNE), is pleased to report that in a recently completed dog efficacy field study, StrixNB was very effective against halitosis (bad breath). The study was conducted on Sheltie dogs. Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms.
The field study was designed to evaluate the effect of StrixNB on bad breath in dogs over a period of 21 days using a Halimeter® to measure the Volatile Sulfur Compounds (VSC) in breath samples. Five Sheltie dogs ranging in age from 2 years to 14 years were used in the study and had varying degrees of bad breath from slight odor to very strong odor. The dogs were kept on the same diet and drinking water with StrixNB added to the drinking water from Day 0 after measuring the initial VSC in their breath.
The VSC measurements were taken 8 times between Day 0 and Day 21 of the study. Dogs with the highest VSC measurements (very strong odor) showed the greatest reduction in bad breath. Day 9 of the study showed a reduction of 50% to 69% in the dogs with the strong odor. After 21 days, the VSC reduction continued to improve to 71% to 82%. The remaining dogs that had no or slight odor also showed VSC reductions but the percentage was lower as the base line was normal. Improvements were recorded in all five dogs with an average reduction of 48%. The level of VSC or halitosis is a strong diagnostic predictor of periodontal disease.
The Halimeter measurements of VSC levels were also compared with the organoleptic assessment of bad breath using judges. There was also a correlation between organoleptic scoring of bad breath and the Halimeter measurement of VSC. Thus, both the methods of measuring bad breath show that StrixNB is very effective against bad breath in dogs.
"Doggie breath has always been a challenge that pet owners have with their dogs and StrixNB is a unique product that attacks the problem head on," stated Gord Froehlich, President and CEO of Kane Biotech. "We have received numerous compliments on StrixNB's breath freshening effect and are excited StrixNB will soon be available to pet owners across Western Canada through their local Veterinary Clinics."
In addition to the measurement of bad breath, other observations in the test animals included a noticeable change in the teeth and gum line in the dogs with very strong bad breath and plaque had started to soften and was easily removable.
StrixNB is a safe and effective drinking water additive to help maintain and promote good dental and oral hygiene for companion animals. StrixNB is xylitol-free, made using 100% human food grade ingredients and registered with the Interim Notification Program of Health Canada for Low Risk Veterinary Health Products (NN.1Q11).
StrixNB works against dental disease-associated bacteria by altering the mouth's environment. It breaks through dental biofilm - a highly structured, matrix-embedded microbial population - leaving bacteria otherwise inaccessible exposed for eradication by a microbial agent.
For more information about our product, please visit our website at www.strixnb.com or like us on Facebook at www.facebook.com/StrixNB.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe", "anticipate", "expect", "intend", "plan", "will", "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
StrixNB™, DispersinB® and Aledex® are registered trademarks of Kane Biotech Inc. All Rights Reserved 2013.
FOR FURTHER INFORMATION PLEASE CONTACT:
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Contact Information:
Pure Advertising and Marketing
Kane Biotech Inc.
President & CEO